Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Mã chứng khoánKROS
Tên công tyKeros Therapeutics Inc
Ngày IPOApr 08, 2020
Giám đốc điều hànhDr. Jasbir Seehra, Ph.D.
Số lượng nhân viên169
Loại chứng khoánOrdinary Share
Kết thúc năm tài chínhApr 08
Địa chỉ1050 Waltham Street, Suite 302
Thành phốLEXINGTON
Sàn giao dịch chứng khoánNASDAQ Global Market Consolidated
Quốc giaUnited States of America
Mã bưu điện02421
Điện thoại16173146297
Trang webhttps://www.kerostx.com/
Mã chứng khoánKROS
Ngày IPOApr 08, 2020
Giám đốc điều hànhDr. Jasbir Seehra, Ph.D.
Tổng cộng
0.00
USD đã được phân phối dưới dạng cổ tức trong 5 năm qua.

Không có dữ liệu